InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
60,258.47
(
1.73%
)
Post# of 252589
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Mufaso post# 249499

Thursday, 11/02/2023 7:02:49 PM

Thursday, November 02, 2023 7:02:49 PM

Post# of 252589
TERN begins phase-1 for oral GLP-1 drug:

https://www.globenewswire.com/news-release/2023/11/02/2772813/0/en/Terns-Pharmaceuticals-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-TERN-601-Oral-GLP-1-Receptor-Agonist-for-Treatment-of-Obesity.html

TERN-601 is a small-molecule GLP-1 receptor agonist; because it’s not a peptide, it presumably will not have the strict fasting requirements of NVO’s oral semaglutide, Rybelsus.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up